Mologen
tigated with the checkpoint inhibitor Yervoy ® (ipilimumab) in various cancer indications within the scope of a Phase I combination study.
Cell-based therapeutic vaccine Our product portfolio includes another proprietary cellbased therapeutic vaccine, MGN1601, to treat advanced renal cancer. The further development of MGN1601 has been shelved for the time being. It is anticipated that this will be re-initiated at a later date, for example following the successful out-licensing of lefitolimod.
Partnering We offer pre- and clinical drug candidates in the highly attractive field of immunotherapies. Due to their known or expected good safety profile they offer as well a tremendous potential for combination therapies to enhance the efficacy of other immunotherapies. MOLOGEN is primarily seeking licensing partners for the TLR9 family with its compounds lefitolimod and EnanDIM® – with the option for flexible cooperation arrangements.
7 th european biotechnology guide 2017
112 | 113